Table 4 Comparison of prospective FEV1 decline, exacerbation rate and respiratory symptoms between those in the discordant group (Ever-smokers with normal FEV1, FEV1/FVC < 0.70 and > LLN) with CT findings of emphysema or functional small airways disease, and those without
From: Heterogeneous burden of lung disease in smokers with borderline airflow obstruction
|  | Ever-smokers with normal FEV1, FEV1/FVC < 0.70 and > LLN (discordant group, n = 161) | |||
|---|---|---|---|---|
With fSAD or emphysema (44%) | Without fSAD or emphysema (56%) | *Adjusted p-value | Unadjusted p-value | |
Annual change in FEV1 (ml/year) | −65.6 ± 113.0 | −59.8 ± 130.6 | 0.26 | 0.79 |
Exacerbation (#/year) | 0.13 ± 0.42 | 0.06 ± 0.24 | 0.90 | 0.25 |
COPD Assessment Test (CAT) | 11.43 ± 7.44 | 9.88 ± 7.25 | 0.55 | 0.22 |
Chronic bronchitis (%) | 14.3 ± 35.3 | 18.3 ± 38.9 | 0.58 | 0.52 |
FEF25–75% % predicted | 60.0 ± 11.6 | 62.2 ± 10.7 | 0.87 | 0.24 |